With the support of a genetic engineering component under the 863 Program, Tailuo TM, a proprietary diabetes drug, developed through combined efforts of pharmaceutical design and research activities, made its debut on November 7, 2004 in Chongqing. Developed by the Chinese Academy of Military Medical Sciences, incubated by the Beijing Pharmaceutical Particle Design Center, and materialized by the Taiji Industrial Group, the new medicine has been granted with a national invention patent, a certificate for new medical products by the State Food and Drug Administration and the associated production permit.

Other innovative drugs developed through the pharmaceutical design process include one IBS drug allowed into phase II clinical trials, and seven others that have completed pre-phase research and are ready for clinical trials. A SPFF asthma drug has applied for clinical trials. Ten more innovative drug candidates entered pre-phase study.

In addition, two drug design demonstration platforms are created in Beijing and Shanghai respectively. Chinese scientists developed a technique for designing and screening high flux medicines, with a capacity for sorting out 500, 000 compounds a day, recorded an efficiency a thousand times faster than conventional means. The internationally advanced new technique has shortened the screening cycle of a new cursor compound, and saved cost for developing new drugs. In collaboration with the information sector, a national pharmaceutical particle design network with 1000 billion connecting knots has been created in Shanghai and Beijing, in a move to facilitate the particle design process for new drugs, and establish a virtual as well as a real research system for the same purpose.

DacoDock, China?痵 first proprietary software system developed by the Chinese University of Science and Technology for pharmaceutical particle design, has completed the design of user friendly interfaces and a working manual, and moved into the testing phase at major domestic pharmaceutical particle design platforms and research institutes.